BioScience

EQS-News: 3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24

Retrieved on: 
Wednesday, March 13, 2024

Adriaan Moelker, CEO BRAIN Biotech AG, states: “Our BioScience segment made a very strong start to the business year.

Key Points: 
  • Adriaan Moelker, CEO BRAIN Biotech AG, states: “Our BioScience segment made a very strong start to the business year.
  • The BRAIN Biotech Holding segment mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing and M&A activities.
  • CFO at BRAIN Biotech AG, Michael Schneiders, takes an optimistic view on the financial year 2023/24: “We aim to continue our organic growth path from the last two years.
  • The BRAIN Biotech Group now targets a revenue range of € 58 million to € 62 million for the new financial year.

EQS-News: Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy

Retrieved on: 
Wednesday, January 17, 2024

January 2024 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry and parent company of the BRAIN Biotech Group, has published the Group´s financial figures for the fiscal year 2022/23.

Key Points: 
  • January 2024 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry and parent company of the BRAIN Biotech Group, has published the Group´s financial figures for the fiscal year 2022/23.
  • Expanding enzyme sales within the BioProducts segment demonstrated the main contribution to organic growth.
  • BRAIN Biotech’s One-BioProducts strategy will deliver significant growth and cost synergies within the segment during the coming years.
  • CEO Adriaan Moelker says: “I am very pleased that our growth strategy is developing in the targeted direction with a second consecutive year of sales expansion above market growth.

EQS-News: BRAIN Biotech AG reports solid 9M numbers despite ongoing high R&D investments and more challenging economic conditions

Retrieved on: 
Wednesday, August 30, 2023

Zwingenberg, Germany, August 30th, 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, today published solid 9M results of FY2022/2023.

Key Points: 
  • Zwingenberg, Germany, August 30th, 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, today published solid 9M results of FY2022/2023.
  • Despite an increasingly challenging economic environment and ongoing high investments especially in its Akribion Genomics genome editing platform, BRAIN Biotech stays on track towards its stated fiscal year targets.
  • The BRAIN Biotech Holding segment mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing and M&A activities.
  • Michael Schneiders, CFO of BRAIN Biotech AG summarizes: "We proactively have to manage the company in an environment of slowing economic growth in conjunction with persistent inflation.

iuvo BioScience Hires Industry Executive to Lead Clinical Research Team

Retrieved on: 
Tuesday, July 18, 2023

ROCHESTER, N.Y., July 18, 2023 /PRNewswire-PRWeb/ -- iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Lacey Powers, MSJ as its new VP, Clinical Research. This hire demonstrates iuvo's ongoing commitment to serving our clients, delivering differentiated expertise across our service offerings, and continued investment in the clinical research business to support the company's growth trajectory.

Key Points: 
  • iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Lacey Powers, MSJ as its new VP, Clinical Research.
  • ROCHESTER, N.Y., July 18, 2023 /PRNewswire-PRWeb/ -- iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Lacey Powers, MSJ as its new VP, Clinical Research.
  • Powers is an experienced clinical research executive who brings over twenty years of diverse experience to this role.
  • Daniel Spasic, Board Chair of iuvo BioScience, said, "We are excited to welcome Lacey to the iuvo family and our clinical development organization.

EQS-News: BRAIN Biotech AG´s Akribion Genomics team successfully competes in Science4Life Venture Cup competition

Retrieved on: 
Wednesday, June 28, 2023

Zwingenberg, Germany, 28 June 2023 – BRAIN Biotech AG is pleased to announce that the Akribion Genomics team has been awarded second place in the Science4Life Venture Cup.

Key Points: 
  • Zwingenberg, Germany, 28 June 2023 – BRAIN Biotech AG is pleased to announce that the Akribion Genomics team has been awarded second place in the Science4Life Venture Cup.
  • Science4Life is the largest German business plan competition for ventures in the fields of Life Sciences, Chemistry and Energy.
  • The Akribion Genomics team develops groundbreaking CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome editing tools, today powered by the BRAIN Biotech AG BioIncubator.
  • Michael Krohn, Co-CEO of Akribion Genomics (in founding), states: "We are honored to receive the silver medal in this very strong competition.

PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.

Retrieved on: 
Friday, June 2, 2023

PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S.

Key Points: 
  • PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S.
  • As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period.
  • In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption.

EQS-News: BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy

Retrieved on: 
Saturday, May 27, 2023

Zwingenberg, Germany, May 25th, 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, today published its half year results, 6M 2022/2023.

Key Points: 
  • Zwingenberg, Germany, May 25th, 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, today published its half year results, 6M 2022/2023.
  • BRAIN Biotech AG has recently bought the two remaining minority stakes in Biocatalysts Ltd. Biocatalysts is now fully owned by BRAIN Biotech AG and will form the nucleus of BRAIN Biotech Group’s ambitious growth strategy to create a global multi-niche enzyme champion.
  • With the publication of the half-year figures BRAIN Biotech AG´s reporting has been changed to three operating business segments plus the management segment BRAIN Biotech Holding.
  • Adriaan Moelker, CEO of BRAIN Biotech AG: "We are well on the way to execute on our ambitious fiscal year targets.

iuvo BioScience Hires Industry Executive to Lead Finance Team

Retrieved on: 
Thursday, May 25, 2023

ROCHESTER, N.Y., May 25, 2023 /PRNewswire-PRWeb/ -- iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Robert (Bobby) McFall, CPA, MBA, as their Director of Finance. This hire demonstrates iuvo's continued commitment to serving our clients, differentiated expertise, and investment in the business to support the company's growth trajectory.

Key Points: 
  • Bobby is a well-established Finance executive who brings years of experience in all aspects of finance and accounting, specifically in the healthcare industry.
  • I look forward to being part of the team and driving the delivery of the strategic plan as well leading the Finance team and setting the stage for long-term success."
  • Daniel Spasic, Board Chair of iuvo BioScience, said, "we are excited to welcome Bobby to the iuvo family.
  • Finally, Ben Burton, CEO of iuvo BioScience, commented, "the timing could not be better for adding Bobby to our team.

Innosphere Ventures, Colorado BioScience Association, and Colorado BioScience Institute Announce the Colorado Life Sciences Incubation Program 2023 Cohort

Retrieved on: 
Wednesday, April 26, 2023

Denver and Fort Collins, Colo., April 26, 2023 (GLOBE NEWSWIRE) -- Innosphere Ventures , Colorado BioScience Association (CBSA), and Colorado BioScience Institute (The Institute) announce the eight startup and scaleup companies that were selected to join the 2023 Colorado Life Sciences Incubation Program.

Key Points: 
  • Denver and Fort Collins, Colo., April 26, 2023 (GLOBE NEWSWIRE) -- Innosphere Ventures , Colorado BioScience Association (CBSA), and Colorado BioScience Institute (The Institute) announce the eight startup and scaleup companies that were selected to join the 2023 Colorado Life Sciences Incubation Program.
  • With funding support from the state of Colorado, the Colorado Life Sciences Incubation Program  provides life sciences startups with a powerful advantage by leveraging the combined expertise and insights of three leading organizations from the state’s life sciences and innovation ecosystem.
  • We remain committed to nurturing and supporting innovative life sciences startups through our unique incubation program, which combines the expertise and resources of Innosphere Ventures, the Colorado Bioscience Association, and the Colorado Bioscience Institute.
  • “Colorado BioScience Association and Colorado BioScience Institute extend a warm welcome to the promising start ups selected for this year’s Colorado Life Sciences Incubation Program cohort,” said Elyse Blazevich, President and CEO of Colorado BioScience Association and President of Colorado BioScience Institute.

iuvo BioScience Hires Industry Executive to Lead Commercial Organization

Retrieved on: 
Tuesday, April 4, 2023

ROCHESTER, N.Y., April 4, 2023 /PRNewswire-PRWeb/ -- iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to biopharmaceutical and medical device customers, today announced it has hired Sanjeev Ganatra, MBA, as their Chief Commercial Officer. This hire demonstrates iuvo's continued commitment to client service, differentiated expertise, and investment in the business to support the company's growth trajectory.

Key Points: 
  • iuvo BioScience, ann industry leading CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to biopharmaceutical and medical device customers, has hired Sanjeev Ganatra, MBA, as their Chief Commercial Officer.
  • Ganatra is a well-established operational and business executive who brings years of experience in sales, marketing, business and corporate development both in pharma service companies as well as commercial organizations.
  • ROCHESTER, N.Y., April 4, 2023 /PRNewswire-PRWeb/ -- iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to biopharmaceutical and medical device customers, today announced it has hired Sanjeev Ganatra, MBA, as their Chief Commercial Officer.
  • Sanjeev's demonstrated expertise in client service is a perfect cultural fit for our team, and his business acumen and performance track record will create value immediately for iuvo BioScience.